173 related articles for article (PubMed ID: 26224770)
1. The Hollow Fiber System Model in the Nonclinical Evaluation of Antituberculosis Drug Regimens.
Chilukuri D; McMaster O; Bergman K; Colangelo P; Snow K; Toerner JG
Clin Infect Dis; 2015 Aug; 61 Suppl 1():S32-3. PubMed ID: 26224770
[No Abstract] [Full Text] [Related]
2. Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience.
Cavaleri M; Manolis E
Clin Infect Dis; 2015 Aug; 61 Suppl 1():S1-4. PubMed ID: 26224766
[TBL] [Abstract][Full Text] [Related]
3. Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
Pasipanodya JG; Nuermberger E; Romero K; Hanna D; Gumbo T
Clin Infect Dis; 2015 Aug; 61 Suppl 1():S10-7. PubMed ID: 26224767
[TBL] [Abstract][Full Text] [Related]
4. Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis.
Johnson CM; Pandey R; Sharma S; Khuller GK; Basaraba RJ; Orme IM; Lenaerts AJ
Antimicrob Agents Chemother; 2005 Oct; 49(10):4335-8. PubMed ID: 16189115
[TBL] [Abstract][Full Text] [Related]
5. Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.
Gumbo T; Pasipanodya JG; Romero K; Hanna D; Nuermberger E
Clin Infect Dis; 2015 Aug; 61 Suppl 1():S25-31. PubMed ID: 26224769
[TBL] [Abstract][Full Text] [Related]
6. Azole antifungals as novel chemotherapeutic agents against murine tuberculosis.
Ahmad Z; Sharma S; Khuller GK
FEMS Microbiol Lett; 2006 Aug; 261(2):181-6. PubMed ID: 16907718
[TBL] [Abstract][Full Text] [Related]
7. Nonclinical models for antituberculosis drug development: a landscape analysis.
Gumbo T; Lenaerts AJ; Hanna D; Romero K; Nuermberger E
J Infect Dis; 2015 Jun; 211 Suppl 3():S83-95. PubMed ID: 26009617
[TBL] [Abstract][Full Text] [Related]
8. Drug resistance in tuberculosis.
al-Orainey IO
J Chemother; 1990 Jun; 2(3):147-51. PubMed ID: 2116504
[TBL] [Abstract][Full Text] [Related]
9. Trench warfare in a battle with TB.
Marshall E
Science; 2008 Jul; 321(5887):362-4. PubMed ID: 18635790
[No Abstract] [Full Text] [Related]
10. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
Gumbo T; Pasipanodya JG; Nuermberger E; Romero K; Hanna D
Clin Infect Dis; 2015 Aug; 61 Suppl 1():S18-24. PubMed ID: 26224768
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.
Brown AN; Drusano GL; Adams JR; Rodriquez JL; Jambunathan K; Baluya DL; Brown DL; Kwara A; Mirsalis JC; Hafner R; Louie A
mBio; 2015 Nov; 6(6):e01741-15. PubMed ID: 26530386
[TBL] [Abstract][Full Text] [Related]
12. Dosing regimens in the treatment of tuberculosis.
Blom-Bülow B
Scand J Infect Dis Suppl; 1990; 74():258-61. PubMed ID: 2129066
[TBL] [Abstract][Full Text] [Related]
13. How can nanoparticles contribute to antituberculosis therapy?
Costa-Gouveia J; Aínsa JA; Brodin P; Lucía A
Drug Discov Today; 2017 Mar; 22(3):600-607. PubMed ID: 28137645
[TBL] [Abstract][Full Text] [Related]
14. [Antitubercular drug therapy. In practice... one should remember].
Duroux P
Rev Prat; 1979 Jun; 29(33):2693-5. PubMed ID: 113864
[No Abstract] [Full Text] [Related]
15. [Resistance to antitubercular drugs in patients with tuberculosis registered in the antituberculosis clinics in Poland 1966-1980].
Szczuka I
Pneumonol Pol; 1982 Oct; 50(10):497-501. PubMed ID: 6820494
[No Abstract] [Full Text] [Related]
16. Present-day treatment of tuberculosis and latent tuberculosis infection.
Pérez-Camacho I; Rivero-Juárez A; Kindelán JM; Rivero A
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 1():41-6. PubMed ID: 21420566
[TBL] [Abstract][Full Text] [Related]
17. [The present attitude to chemotherapy in tuberculosis in adults].
Mehić B; Zutić H
Med Arh; 1987; 41(6):339-45. PubMed ID: 3152080
[No Abstract] [Full Text] [Related]
18. [Influence of various combinations of antitubercular agents on the course of experimental tuberculous infections and development of drug resistance].
Durisić M; Davidović C; Jovanović M; Marković Lj
Glas Srp Akad Nauka Med; 1975; (26):17-23. PubMed ID: 816709
[No Abstract] [Full Text] [Related]
19. Fighting tuberculosis: old drugs, new formulations.
Blasi P; Schoubben A; Giovagnoli S; Rossi C; Ricci M
Expert Opin Drug Deliv; 2009 Sep; 6(9):977-93. PubMed ID: 19678791
[TBL] [Abstract][Full Text] [Related]
20. Introduction to a formal theory of the dosage regimen calculation in intermittent chemotherapy of tuberculosis.
Bercea O; Bonciocat N
Arzneimittelforschung; 1970 Feb; 20(2):241-5. PubMed ID: 4986038
[No Abstract] [Full Text] [Related]
[Next] [New Search]
